Dr Jan Lundberg Joins IAG’s Board of Directors

IAG Appoints Jan Lundberg as Chair of Scientific Advisory Board

IAG Expands Scientific Leadership, Accelerating Growth and Innovation in Drug Development

 

Image Analysis Group (IAG), a rapidly expanding partner to life science companies, has appointed Dr. Jan Lundberg, MD PhD, as Chairman of its Scientific Advisory Board, marking a significant milestone in the company’s growth as a scientifically-driven organization.

Dr. Lundberg brings over 22 years of experience in global pharmaceutical R&D, having led research at industry giants Eli Lilly and AstraZeneca. His impressive track record includes the discovery of more than 200 candidate drugs and 22 approved products across multiple therapeutic areas, demonstrating the depth of expertise he brings to IAG.

This strategic appointment underscores IAG’s commitment to scientific excellence and innovation in optimizing bio-pharmaceutical R&D. By leveraging Dr. Lundberg’s extensive experience, IAG aims to enhance its ability to deliver cutting-edge solutions in AI and quantitative imaging to drug developers worldwide.

IAG’s proprietary cloud-based platform, Dynamika™, combined with its expanding team of in-house scientists and imaging experts, positions the company at the forefront of accelerating clinical trials and improving patient outcomes. The addition of Dr. Lundberg to both the Scientific Advisory Board and corporate board as a Non-Executive Director further strengthens IAG’s scientific and strategic capabilities.

Dr. Olga Kubassova, CEO and founder of IAG, emphasized the company’s rapid growth and expanding partnerships with major pharmaceutical companies. This expansion, coupled with the appointment of industry veterans like Dr. Lundberg, showcases IAG’s evolution into a global scientific powerhouse dedicated to revolutionizing drug development processes.

As IAG continues to scale its operations and scientific expertise, drug developers can expect even more innovative solutions to de-risk clinical development, accelerate study outcomes, and bring life-saving therapies to patients faster than ever before.

News
Events